Conclusions and future directions
cognitive decline
This is one of the first studies to demonstrate that a medication for prevention of cognitive decline during chemotherapy is feasible. As indicated above, we plan to extend this work to next conduct a RCT of memantine in this patient population and treatment setting. Because CRCI is a heterogeneous phenomenon with some patients experiencing substantial decline and others being unaffected, future research aimed at recognizing who is most at risk for cognitive decline during chemotherapy and who may experience most benefit from specific interventions is needed.